Research Experience

Sharp/Mesa Vista Hospital, 7850 Vista Hill Avenue, San Diego CA 92123 / (Sub-investigator)


  • Pfizer R-0548: double blind study comparing ziprasidone with olanzapine for schizophrenia or schizoaffective disorder.
  • Abbott M97-696: double blind parallel group comparison of Depakote ER/placebo for acute manic subjects.
  • HGGW, Eli Lilly Pharmaceuticals: Double blind Zyprexa/placebo controlled for Bipolar Disorder.
  • M97-697/6 Abbott Labs: double blind Depakote/placebo controlled for Bipolar Disorder.
  • Lilly HGHB: double blind comparison of short acting IM olanzapine, short acting IM haloperedol and IM placebo for schizophrenia.
  • Lilly HGHX: double blind placebo controlled comparison of short acting IM olanzapine, short acting IM lorazepam, and IM placebo for agitation in patients with Alzheimer type dementia, vascular dementia and mixed dementia.
  • Lilly HGHW: double blind comparison of short acting IM olanzapine, short acting IM lorazepam and IM placebo for manic bipolar disorder.
  • Bristol-Myers Squibb CN138-007: double blind placebo controlled study of two fixed doses of Aripiprazole in acute mania.
  • Sumitomo: Phase II study of two dose levels of SM-13496 US.Placebo for Schizophrenia.
  • AstraZeneca 5077IL/0041 Seroquel ER: double blind comparison of sustained-release Seroquel and placebo in schizophrenia.


  • M100907 Protocol 3010: double blind investigationl/placebo for Schizophrenia.
  • E1D-MC-HGGA Eli Lilly Pharmaceutical: double blind Zyprexa/placebo for psychotic depression.
  • Lilly HGHH: open label studyto show reduction in prolactin level in schizophrenic patients when switched from conventional antipsychotic or respiridone to olanzapine.
  • Hoechst Marion Roussel 3005: open label, long term safety study of M100907 for schizophrenic and schizoaffective subjects who participated in Protocal 3001 (a double blind 6 week study).
  • Hoechst Marion Roussel 3010: open label study of an investigational study drug once daily for long-term treatment for schizophrenia or other psychotic disorders.
  • Lilly HGHC: study to estimate the rate of hyperprolactinemia in schizophrenia, schizophreniform, and schizoaffective subjects treated with conventional antipsychotic drugs or respiridone.
  • Pfizer R-0585: open label extension study of safety and efficacy of long-term treatment of ziprasidone 40-160mg daily.
  • Novartis ABA-451: randomized parallel group comparison of Clozoril versus Zyprexa in the reduction of suicidality in schizophrenia or schizoaffective disorder.
  • Janssen RIS-INT-81: nine week open label safety study of single dose ranges of Respiridone in manic episodes with Bipolar I Disorder.
  • Lilly HGJB: controlled trial of Olanzapine vs. Quetiapine in Schizophrenic and Schizoaffective subjects with prominentnegative symptoms.
  • Shire Laboratories 105.303: open label study of extended release Carbamazepine in Bipolar Disorder.
  • Bristo-Myers Squibb CN138-037: open label long term study of Aripiprazole in the maintenance treatment of bipolar disorder.
  • Pfizer R-0570: double blind continuation protocol for patients completing R-0548.
  • Lilly HGHZ: double blind study comparing the combination of Olanzapine and Fluoxetine in treatment resistant depression without psychotic features.
  • Lilly F1D-EW-LOBE: a study to assess the safety, tolerability and pharmacokinetics of single and multiple doses of and intramuscular formulation of depot Olanzapine (Pamoate Salt) in stable schizophrenic subjects.
  • Lilly F1D-US-HGJU: a controlled trial of Olanzapine vs. Ziprasidone in the treatment of schizophrenic/schizoaffective subjects with comorbid depression.
  • Janssen RIS-USA-259: open label trial exploring a switching regimen from oral neuroleptics, other than risperidone, to risperidone depot microspheres.
  • Janssen RIS-USA-265: open label long-term trial of at least 1 yr duration of 25, 37.5, and 50mg. of Resperidone long acting microspheres given every 2 weeks in the treatment of schizophrenia.
  • Pfizer A2501024: A 12 week multicenter, randomized, double blind, placebo controlled evaluation of Donepezil Hydrochloride as adjunctive therapy in the treatment of cognitive impairment in patients with schizophrenia or schizoaffective disorder.
  • Lilly F1D-MC-S014: Phase 4, parallel, double-blinded randomized study assessing the effect of therapeutically effective doses of antipsychotic therapy (olanzapine and risperidone) on insulin sensitivity over a 12 week period in patients with schizophrenia or schizoaffective disorder.


  • Janssen RIS-121: double blind study comparinginjections of resperidone depot/placebo every 2 weeks for schizophrenia and schizoaffective disorder.
  • Abbott Depakote: comparison of Depakote and Zyprexa for bipolar disorder.
  • Lilly HGHQ: double blind study to assess olanzapine versus divalproex for improving the overall manic symptomalogy in patients with bipolar manic or mixed without psychotic features for 3 weeks inpatient and 12 months outpatient.
  • Janssen RIS-USA-239: flexible dosage ranges of Risperidone vs. Placebo in manic episodes with Bipolar I disorder.
  • Bristol-Myers Squibb CN138-032: